Creo Medical Group PLC Speedboat RS2 advances beyond initial pilot centre

TIDMCREO

Creo Medical Group PLC

29 November 2017

Creo Medical Group plc

("Creo" or "the Company")

Speedboat RS2 advances beyond initial pilot centre

Speedboat RS2 utilised at second NHS site

Chepstow, South Wales - 29 November 2017 - Creo Medical Group plc (AIM: CREO) is pleased to announce that Speedboat RS2 has been used by a second Gastroenterologist at a second NHS site to treat further patients. This follows the announcement earlier this year with the first patient being treated at St Marks hospital in London.

Initial feedback from the first two cases at this site confirmed the removal of lesions under local anaesthetic with a procedure time of under one hour. The patients were discharged on the same day and are now under routine follow-up and monitoring. We await final histology results.

Craig Gulliford, Chief Executive Officer of Creo Medical, commented: "We are excited by today's announcement as it provides further validation of our technology. It is incredible that these patients were conscious, talking to the endoscopist and able to watch the procedure live on screen. While we need to collect additional supportive clinical data, we are encouraged by the results we've seen to date. We believe that procedures like this have the potential to eliminate the need for subsequent bowel surgery, with the obvious patient benefits aligned with material advantages to the healthcare system in terms of cost and patient safety."

 
 Contacts 
 Creo Medical:                   Cenkos:                 FTI Consulting: 
 Richard Rees                    Camilla Hume / Mark     Brett Pollard 
  [phone]              Connelly (NOMAD)        / Mo Noonan 
  [e-mail]    Michael Johnson /       [phone] 
                                  Russell Kerr (Sales)    1000 
                                  [phone]     [e-mail] 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on improving patient outcomes by applying microwave and radiowave energy to a range of minimally invasive surgical devices. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency, for precise localised cutting, and microwaves, for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy; an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAPGGMUGUPMUUB

(END) Dow Jones Newswires

November 29, 2017 02:01 ET (07:01 GMT)